Author/Editor     Almeda, J; Casabona, J; Simon, B; Gerard, M; Rey, D; Puro, V; Thomas, T; Tomažič, Janez
Title     Proposed recommendations for the management of HIV post-exposure prophylaxis after sexual, injecting drug or other exposured in Europe
Type     članek
Source     Euro Surveill
Vol. and No.     Letnik 9, št. 6
Publication year     2004
Volume     str. 35-40
Language     eng
Abstract     Post-exposure prophyIaxis (PEP) is the standard of care for a healthcare worker (HCW) accidentally exposed to an HIV infected source person (occupafional exposure); but this is not the case-for non-occupational exposures. Very few national guidelines exist for the management of non-occupational exposures to HIV in Europe, contrarily to the occupational ones. The administration of nonoccupational post-exposure prophylaxis (NONOPEP) for HIV may be justified by: a biological plausibility, the effectiveness of PEP in animal studies and occupational exposures in humans, efficacy in the prevention of mother to child HIV transmission, and cost effectiveness studies. These evidences, the similar risk of HIV transmission for certain non-occupational exposures to occupational ones, and the conflicting information about attitudes and practices among physicians on NONOPEP led to the proposal of these European recommendations. Participant members of the European project on HIV NONOPEP, funded by the European Commission, and acknewledged as experts in bloodborne pathogen transmission and prevention, met from December 2000 to December 2002 at three formal meetings and a two day workshop for a literature review on risk exposure assessment and the development of the European recommendations for the management of HIV NONOPEP. NONOPEP is recommended in unprotected receptive anal sex and needle or syringe exchange when the source persen is known as H IV positive or from a populatien group with high HIV prevalence. Any combination of drugs available for HIV infected patients can be used as PEP and the simplest and least toxic regimens are to be prefered. (Abstract truncated at 2000 characters).
Descriptors     HIV INFECTIONS
HIV
AZITHROMYCIN
ZIDOVUDINE
LAMIVUDINE
CHEMOPREVENTION
RISK FACTORS
PRACTICE GUIDELINES